Esperion Therapeutics Inc(ESPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.1 | Insider Own | - | Shs Outstand | 257.4M | Perf Week | - |
| Market Cap | 0.82B | Forward P/E | 10.48 | EPS next Y | 273.33% | Insider Trans | - | Shs Float | 242.0M | Perf Month | 0.63% |
| Enterprise Value | 1.21B | PEG | - | EPS next Q | -0.03 | Inst Own | 71.64% | Short Float | 7.19% | Perf Quarter | 61.42% |
| Income | -0.01B | P/S | 1.96 | EPS this Y | -59.09% | Inst Trans | 9.55% | Short Ratio | 1.13 | Perf Half Y | 6.71% |
| Sales | 0.42B | P/B | - | EPS next 5Y | - | ROA | -1.89% | Short Interest | 17.40M | Perf YTD | -14.05% |
| Book/sh | -1.2 | P/C | 5.24 | EPS past 3/5Y | 68.58% 53.87% | ROE | - | 52W High | -23.83% ($4.18) | Perf Year | 156.45% |
| Cash/sh | 0.61 | P/FCF | - | Sales past 3/5Y | 74.8% 12.12% | ROIC | -4.84% | 52W Low | 189.09% ($1.10) | Perf 3Y | 97.52% |
| Dividend Est. | - | EV/EBITDA | 15.9 | EPS Y/Y TTM | 92.51% | Gross Margin | 68.38% | Volatility(W/M) | 0.63% 0.57% | Perf 5Y | -83.5% |
| Dividend TTM | - | EV/Sales | 2.88 | Sales Y/Y TTM | 61.13% | Oper. Margin | 18.12% | ATR (14) | 0.02 | Perf 10Y | -71.58% |
| Dividend Ex-Date | - | Quick Ratio | 1.18 | EPS Q/Q | 51.43% | Profit Margin | -1.77% | RSI (14) | 64.75 | Recom | 3.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.53 | Sales Q/Q | 23.25% | SMA20 | 0.6% ($3.16) | Beta | 1.09 | Target Price | $3.16 |
| Payout | - | Debt/Eq | - | Earnings | 2026/5/8 | SMA50 | 2.72% ($3.1) | Rel Volume | 0 | Prev Close | $3.18 |
| Employees | 294 | LT Debt/Eq | - | EPS/Sales Surpr. | -169.54% -5.23% | SMA200 | 4.1% ($3.05) | Avg Volume(3M) | 15.45M | Price | $3.18 |
| IPO | 2013/6/26 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🫀 Esperion Therapeutics (ticker ESPR) is a US pharmaceutical company headquartered in Ann Arbor, Michigan, with its core assets being the oral LDL-cholesterol-lowering drug bempedoic acid (NEXLETOL) and the bempedoic acid/ezetimibe combination (NEXLIZET). The company focuses on treating chronic cardiovascular and metabolic diseases, with a goal of reducing cardiovascular risk in patients who cannot tolerate statins.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
ESPR keeps an operating profit but posts a net loss
Of every $100 in sales, $18.12 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -59.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $196. Peers typically go for $154.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 71.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #35 of 84 in the industry
Based on market cap of $819M.
HROW#33 Harrow Inc $1B PER - 
AMPH#34 Amphastar Pharmaceuticals Inc $1B PER 15.0 ESPR#35 Esperion Therapeutics Inc $819M PER - 
COLL#35 Collegium Pharmaceutical Inc $749M PER 18.6 
IRWD#36 Ironwood Pharmaceuticals Inc $580M PER 4.6 
FAQ
What kind of company is ESPR?
ESPR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ESPR?
The market cap of ESPR is approximately $819M, ranking 2,797 within its sector.
What is the 52-week high and low for ESPR?
ESPR has recorded a 52-week high of $4.18 and a low of $1.10.
